Home・Akciju saraksts・Organon & Co

Organon & Co

Slēgts

SektorsVeselības aprūpe

13.77

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

13.77

Max

13.77

Galvenie mērījumi
By Trading Economics
Ienākumi	-292M -146M
Pārdošana	98M 1.6B
P/E Sektora vidējais	17.641 56.659
EPS	0.8
Dividenžu ienesīgums	0.58
Peļņas marža	-9.355
Darbinieki	10,000
EBITDA	-38M 371M

Dividendes
By Acuity
Dividenžu ienesīgums Sektora vidējais	0.58% 2.18%
Nākamie ieņēmumi	2026. g. 9. nov.
Nākamais dividenžu datums	2026. g. 10. sept.
Nākamais Ex dividenžu datums	2026. g. 19. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	63M 3.6B
Iepriekšējā atvēršanas cena	13.77
Iepriekšējā slēgšanas cena	13.77

Ziņu noskaņojums

By Acuity

75%

25%

306 / 339 Rangs Healthcare

Organon & Co Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. sept. 20:08 UTC

Organon & Co. shares are trading roughly flat, showing little change since Tuesday's close, amid stability near the upper end of their one-month range.

2026. g. 1. sept. 23:01 UTC

Organon & Co. shares are lower in after-market trading, continuing a downward trend amid broader market unease over economic data indicating a growth slowdown.

2026. g. 28. aug. 19:26 UTC

Organon & Co. shares are trading roughly flat, with no specific news identified. The stock remains near the upper end of its one-month trading range.

2026. g. 27. aug. 23:01 UTC

Shares of Organon & Co. traded lower in after-market hours, continuing a decline observed earlier in the session without any specific company news identified.

2026. g. 25. aug. 19:36 UTC

Organon & Co. shares are near unchanged, trading within a narrow range with no specific news identified during Tuesday's session.

2026. g. 24. aug. 23:02 UTC

Organon & Co shares are trading lower in after-market hours. Broader geopolitical tensions, particularly the U.S.-Iran situation, may be influencing market sentiment.

2026. g. 21. aug. 23:41 UTC

Organon & Co. shares are lower in after-hours trading, following a decline from earlier highs and reaching a session low. No specific news was identified.

2026. g. 20. aug. 22:01 UTC

Organon & Co shares are trading lower in after-market hours, continuing a downward trend since Thursday's close without any specific news to explain the movement.

2026. g. 19. aug. 23:01 UTC

Organon & Co shares declined in after-hours trading, reflecting unusual weakness since Wednesday's close. The stock is near the lower end of its one-month range.

2026. g. 18. aug. 23:51 UTC

Organon & Co shares are higher in after-market trading, reaching a maximum cumulative return shortly after Tuesday's close. No specific news was identified.

2026. g. 14. aug. 19:26 UTC

Organon & Co. shares are trading roughly flat, remaining above their 20-day moving average and near the upper end of their one-month range.

2026. g. 13. aug. 23:11 UTC

Organon & Co. shares are trading lower in after-market hours, despite an initial uptick, and remain near the upper end of their one-month trading range.

2026. g. 7. aug. 20:06 UTC

Shares of Organon & Co. are higher today, continuing a trend since Thursday's close amid a broader market increase. No specific company news was identified.

2026. g. 6. aug. 23:11 UTC

Shares of Organon & Co. are trading lower in after-market hours, reflecting routine action within its one-month trading range. No specific news was identified.

Salīdzinājums

Cenas izmaiņa

Organon & Co Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Organon & Co — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

306 / 339 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Organon & Co

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.